nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ALB—Captopril—systemic scleroderma	0.0744	0.168	CbGbCtD
Tacrolimus—ALB—Mycophenolate mofetil—systemic scleroderma	0.0585	0.133	CbGbCtD
Tacrolimus—ABCB1—Lisinopril—systemic scleroderma	0.052	0.118	CbGbCtD
Tacrolimus—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0471	0.107	CbGbCtD
Tacrolimus—ALB—Prednisone—systemic scleroderma	0.0468	0.106	CbGbCtD
Tacrolimus—ABCB1—Captopril—systemic scleroderma	0.0389	0.0881	CbGbCtD
Tacrolimus—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0306	0.0694	CbGbCtD
Tacrolimus—ABCB1—Prednisone—systemic scleroderma	0.0245	0.0555	CbGbCtD
Tacrolimus—ALB—Methotrexate—systemic scleroderma	0.0235	0.0532	CbGbCtD
Tacrolimus—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0183	0.0416	CbGbCtD
Tacrolimus—CYP3A4—Prednisone—systemic scleroderma	0.0147	0.0332	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—systemic scleroderma	0.0123	0.0278	CbGbCtD
Tacrolimus—FKBP1A—ALK1 signaling events—SMAD7—systemic scleroderma	0.00419	0.0456	CbGpPWpGaD
Tacrolimus—MTOR—blood vessel—systemic scleroderma	0.00406	0.0935	CbGeAlD
Tacrolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—SMAD7—systemic scleroderma	0.00355	0.0386	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—AIF1—systemic scleroderma	0.00307	0.0333	CbGpPWpGaD
Tacrolimus—ABCA5—tendon—systemic scleroderma	0.00287	0.066	CbGeAlD
Tacrolimus—PPP3CA—connective tissue—systemic scleroderma	0.00282	0.0649	CbGeAlD
Tacrolimus—MTOR—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.0028	0.0304	CbGpPWpGaD
Tacrolimus—PPP3CA—smooth muscle tissue—systemic scleroderma	0.00258	0.0593	CbGeAlD
Tacrolimus—ABCA5—lung—systemic scleroderma	0.00252	0.0579	CbGeAlD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—CTLA4—systemic scleroderma	0.00249	0.027	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta receptor signaling—SMAD7—systemic scleroderma	0.00241	0.0262	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—AIF1—systemic scleroderma	0.00238	0.0259	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—SMAD7—systemic scleroderma	0.00234	0.0254	CbGpPWpGaD
Tacrolimus—FKBP1A—Alpha-synuclein signaling—BLK—systemic scleroderma	0.00223	0.0243	CbGpPWpGaD
Tacrolimus—PPP3CA—Physiological and Pathological Hypertrophy  of the Heart—EDN1—systemic scleroderma	0.0022	0.0239	CbGpPWpGaD
Tacrolimus—MTOR—EGFR-dependent Endothelin signaling events—EDN1—systemic scleroderma	0.00218	0.0236	CbGpPWpGaD
Tacrolimus—MTOR—connective tissue—systemic scleroderma	0.00208	0.0479	CbGeAlD
Tacrolimus—PPP3CA—digestive system—systemic scleroderma	0.00203	0.0469	CbGeAlD
Tacrolimus—PPP3CA—tendon—systemic scleroderma	0.00194	0.0446	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—systemic scleroderma	0.0019	0.0438	CbGeAlD
Tacrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—SMAD7—systemic scleroderma	0.0019	0.0206	CbGpPWpGaD
Tacrolimus—MTOR—skin of body—systemic scleroderma	0.00188	0.0433	CbGeAlD
Tacrolimus—FKBP1A—connective tissue—systemic scleroderma	0.00187	0.0431	CbGeAlD
Tacrolimus—PPP3CA—BCR signaling pathway—CSK—systemic scleroderma	0.00179	0.0194	CbGpPWpGaD
Tacrolimus—FKBP1A—smooth muscle tissue—systemic scleroderma	0.00171	0.0394	CbGeAlD
Tacrolimus—PPP3CA—lung—systemic scleroderma	0.0017	0.0391	CbGeAlD
Tacrolimus—FKBP1A—skin of body—systemic scleroderma	0.00169	0.0389	CbGeAlD
Tacrolimus—MTOR—IFN-gamma pathway—SMAD7—systemic scleroderma	0.00158	0.0171	CbGpPWpGaD
Tacrolimus—PPP3CA—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00154	0.0168	CbGpPWpGaD
Tacrolimus—MTOR—digestive system—systemic scleroderma	0.0015	0.0346	CbGeAlD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.0015	0.0163	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.0015	0.0163	CbGpPWpGaD
Tacrolimus—MTOR—tendon—systemic scleroderma	0.00143	0.0329	CbGeAlD
Tacrolimus—FKBP1A—digestive system—systemic scleroderma	0.00135	0.0311	CbGeAlD
Tacrolimus—PPP3CA—Spinal Cord Injury—SELP—systemic scleroderma	0.00134	0.0145	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta receptor signaling—CTGF—systemic scleroderma	0.00133	0.0145	CbGpPWpGaD
Tacrolimus—FKBP1A—tendon—systemic scleroderma	0.00129	0.0296	CbGeAlD
Tacrolimus—MTOR—lung—systemic scleroderma	0.00126	0.0289	CbGeAlD
Tacrolimus—PPP3CA—Spinal Cord Injury—RHOB—systemic scleroderma	0.00125	0.0136	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.00116	0.0126	CbGpPWpGaD
Tacrolimus—FKBP1A—lung—systemic scleroderma	0.00113	0.026	CbGeAlD
Tacrolimus—FKBP1A—Spinal Cord Injury—SELP—systemic scleroderma	0.00104	0.0113	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)—TGFB1—systemic scleroderma	0.000984	0.0107	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—SELP—systemic scleroderma	0.000975	0.0106	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—RHOB—systemic scleroderma	0.000967	0.0105	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000954	0.0104	CbGpPWpGaD
Tacrolimus—ORM1—lung—systemic scleroderma	0.000884	0.0204	CbGeAlD
Tacrolimus—MTOR—IL4-mediated signaling events—COL1A2—systemic scleroderma	0.000858	0.00933	CbGpPWpGaD
Tacrolimus—MTOR—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.000856	0.0093	CbGpPWpGaD
Tacrolimus—ABCB1—blood vessel—systemic scleroderma	0.000844	0.0194	CbGeAlD
Tacrolimus—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000836	0.00908	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD247—systemic scleroderma	0.0008	0.00869	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CSK—systemic scleroderma	0.00077	0.00836	CbGpPWpGaD
Tacrolimus—MTOR—Interferon type I signaling pathways—STAT4—systemic scleroderma	0.000766	0.00833	CbGpPWpGaD
Tacrolimus—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	0.000754	0.00819	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CD247—systemic scleroderma	0.000724	0.00786	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.000714	0.00776	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—STAT4—systemic scleroderma	0.000704	0.00765	CbGpPWpGaD
Tacrolimus—FKBP1A—ALK1 signaling events—TGFB1—systemic scleroderma	0.000667	0.00725	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.00065	0.00706	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL1A—systemic scleroderma	0.000633	0.00688	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.000611	0.00664	CbGpPWpGaD
Tacrolimus—CYP3A5—digestive system—systemic scleroderma	0.000589	0.0136	CbGeAlD
Tacrolimus—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.000587	0.00638	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000577	0.00627	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.000566	0.00615	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFB1—systemic scleroderma	0.000565	0.00614	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—CSK—systemic scleroderma	0.000557	0.00605	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CTLA4—systemic scleroderma	0.000549	0.00596	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000535	0.00581	CbGpPWpGaD
Tacrolimus—MTOR—VEGFR2 mediated vascular permeability—NOS3—systemic scleroderma	0.000535	0.00581	CbGpPWpGaD
Tacrolimus—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000501	0.00544	CbGpPWpGaD
Tacrolimus—CYP3A5—lung—systemic scleroderma	0.000492	0.0113	CbGeAlD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL1A—systemic scleroderma	0.000491	0.00533	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000477	0.00519	CbGpPWpGaD
Tacrolimus—PPP3CA—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000473	0.00513	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—CD40LG—systemic scleroderma	0.000459	0.00499	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—IL1B—systemic scleroderma	0.000455	0.00494	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—systemic scleroderma	0.000452	0.00491	CbGpPWpGaD
Tacrolimus—CYP3A4—digestive system—systemic scleroderma	0.000442	0.0102	CbGeAlD
Tacrolimus—ALB—Folate Metabolism—CSF1—systemic scleroderma	0.00044	0.00478	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—CCL2—systemic scleroderma	0.000435	0.00473	CbGpPWpGaD
Tacrolimus—ALB—Platelet degranulation—SELP—systemic scleroderma	0.000391	0.00424	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000384	0.00418	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta receptor signaling—TGFB1—systemic scleroderma	0.000383	0.00416	CbGpPWpGaD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000376	0.00409	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000372	0.00404	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000372	0.00404	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000365	0.00396	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—CSK—systemic scleroderma	0.000355	0.00386	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000352	0.00382	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—CCL2—systemic scleroderma	0.000338	0.00367	CbGpPWpGaD
Tacrolimus—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000337	0.00366	CbGpPWpGaD
Tacrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.000335	0.00364	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL1B—systemic scleroderma	0.00033	0.00359	CbGpPWpGaD
Tacrolimus—MTOR—IFN-gamma pathway—IL1B—systemic scleroderma	0.000323	0.00351	CbGpPWpGaD
Tacrolimus—ABCB1—digestive system—systemic scleroderma	0.000313	0.0072	CbGeAlD
Tacrolimus—PPP3CA—Spinal Cord Injury—MMP9—systemic scleroderma	0.000311	0.00338	CbGpPWpGaD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000306	0.00332	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000303	0.00329	CbGpPWpGaD
Tacrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFB1—systemic scleroderma	0.000302	0.00328	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—ITGAM—systemic scleroderma	0.0003	0.00326	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD247—systemic scleroderma	0.0003	0.00326	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—BLK—systemic scleroderma	0.000288	0.00313	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—TNFAIP3—systemic scleroderma	0.000281	0.00305	CbGpPWpGaD
Tacrolimus—ABCB1—lung—systemic scleroderma	0.000261	0.00601	CbGeAlD
Tacrolimus—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.00026	0.00283	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000257	0.00279	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL1B—systemic scleroderma	0.000256	0.00278	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000249	0.0027	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IL1B—systemic scleroderma	0.000247	0.00269	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—SMAD7—systemic scleroderma	0.000244	0.00265	CbGpPWpGaD
Tacrolimus—MTOR—Leptin signaling pathway—NOS3—systemic scleroderma	0.000243	0.00264	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—MMP9—systemic scleroderma	0.000241	0.00262	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000231	0.00251	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—RHOB—systemic scleroderma	0.000223	0.00243	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—TGFBI—systemic scleroderma	0.000223	0.00242	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000209	0.00228	CbGpPWpGaD
Tacrolimus—MTOR—Leptin signaling pathway—IL1B—systemic scleroderma	0.000207	0.00225	CbGpPWpGaD
Tacrolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000206	0.00224	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000199	0.00216	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000193	0.0021	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000192	0.00208	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.00019	0.00207	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SMAD7—systemic scleroderma	0.000189	0.00205	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CSK—systemic scleroderma	0.000186	0.00202	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000183	0.00199	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IRF5—systemic scleroderma	0.000183	0.00199	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000182	0.00198	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.000178	0.00194	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HSPG2—systemic scleroderma	0.000178	0.00193	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD247—systemic scleroderma	0.000175	0.0019	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IRF8—systemic scleroderma	0.000175	0.0019	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ITGAM—systemic scleroderma	0.000175	0.0019	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000174	0.00189	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000173	0.00188	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—NOS3—systemic scleroderma	0.000173	0.00188	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFBI—systemic scleroderma	0.000173	0.00188	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000173	0.00187	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CSK—systemic scleroderma	0.000172	0.00186	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SMAD7—systemic scleroderma	0.000171	0.00185	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000164	0.00178	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—TNFAIP3—systemic scleroderma	0.000164	0.00178	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000163	0.00177	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000162	0.00176	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—BLK—systemic scleroderma	0.000162	0.00176	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD247—systemic scleroderma	0.000161	0.00175	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000158	0.00172	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—CCL2—systemic scleroderma	0.000148	0.00161	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000147	0.0016	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000147	0.0016	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—IL1A—systemic scleroderma	0.000145	0.00158	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000138	0.0015	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HSPG2—systemic scleroderma	0.000138	0.0015	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000135	0.00147	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CSK—systemic scleroderma	0.000134	0.00145	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CSK—systemic scleroderma	0.000133	0.00145	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CTLA4—systemic scleroderma	0.000132	0.00144	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SMAD7—systemic scleroderma	0.000132	0.00144	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RHOB—systemic scleroderma	0.000132	0.00143	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000131	0.00143	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD247—systemic scleroderma	0.000131	0.00142	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ITGAM—systemic scleroderma	0.000131	0.00142	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD247—systemic scleroderma	0.000126	0.00137	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD247—systemic scleroderma	0.000125	0.00136	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HSPG2—systemic scleroderma	0.000124	0.00135	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000123	0.00133	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TNFAIP3—systemic scleroderma	0.000123	0.00133	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CSK—systemic scleroderma	0.00012	0.00131	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000118	0.00128	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000118	0.00128	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—BLK—systemic scleroderma	0.000116	0.00126	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EDN1—systemic scleroderma	0.000114	0.00124	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL1B—systemic scleroderma	0.000113	0.00122	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-DQB1—systemic scleroderma	0.000109	0.00118	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SMAD7—systemic scleroderma	0.000106	0.00115	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL1A—systemic scleroderma	0.000104	0.00113	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD40LG—systemic scleroderma	0.000103	0.00112	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RHOB—systemic scleroderma	0.000102	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFBI—systemic scleroderma	9.72e-05	0.00106	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HSPG2—systemic scleroderma	9.65e-05	0.00105	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CTLA4—systemic scleroderma	9.52e-05	0.00103	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CSK—systemic scleroderma	9.32e-05	0.00101	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	8.95e-05	0.000972	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SELP—systemic scleroderma	8.93e-05	0.00097	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	8.57e-05	0.000202	CcSEcCtD
Tacrolimus—Anxiety—Mycophenolate mofetil—systemic scleroderma	8.56e-05	0.000202	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	8.55e-05	0.000202	CcSEcCtD
Tacrolimus—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	8.55e-05	0.000928	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Azathioprine—systemic scleroderma	8.54e-05	0.000202	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	8.54e-05	0.000202	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	8.53e-05	0.000202	CcSEcCtD
Tacrolimus—Insomnia—Lisinopril—systemic scleroderma	8.5e-05	0.000201	CcSEcCtD
Tacrolimus—Discomfort—Mycophenolate mofetil—systemic scleroderma	8.49e-05	0.000201	CcSEcCtD
Tacrolimus—Paraesthesia—Lisinopril—systemic scleroderma	8.44e-05	0.0002	CcSEcCtD
Tacrolimus—Vomiting—Captopril—systemic scleroderma	8.44e-05	0.0002	CcSEcCtD
Tacrolimus—Dry mouth—Mycophenolate mofetil—systemic scleroderma	8.4e-05	0.000199	CcSEcCtD
Tacrolimus—Dyspnoea—Lisinopril—systemic scleroderma	8.38e-05	0.000198	CcSEcCtD
Tacrolimus—Rash—Captopril—systemic scleroderma	8.37e-05	0.000198	CcSEcCtD
Tacrolimus—Dermatitis—Captopril—systemic scleroderma	8.36e-05	0.000198	CcSEcCtD
Tacrolimus—Somnolence—Lisinopril—systemic scleroderma	8.36e-05	0.000198	CcSEcCtD
Tacrolimus—ALB—Hemostasis—RHOB—systemic scleroderma	8.34e-05	0.000906	CbGpPWpGaD
Tacrolimus—Headache—Captopril—systemic scleroderma	8.32e-05	0.000197	CcSEcCtD
Tacrolimus—Confusional state—Mycophenolate mofetil—systemic scleroderma	8.31e-05	0.000196	CcSEcCtD
Tacrolimus—Dyspepsia—Lisinopril—systemic scleroderma	8.28e-05	0.000196	CcSEcCtD
Tacrolimus—Abdominal pain—Mycophenolic acid—systemic scleroderma	8.25e-05	0.000195	CcSEcCtD
Tacrolimus—Body temperature increased—Mycophenolic acid—systemic scleroderma	8.25e-05	0.000195	CcSEcCtD
Tacrolimus—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	8.24e-05	0.000195	CcSEcCtD
Tacrolimus—Oedema—Mycophenolate mofetil—systemic scleroderma	8.24e-05	0.000195	CcSEcCtD
Tacrolimus—Asthma—Methotrexate—systemic scleroderma	8.21e-05	0.000194	CcSEcCtD
Tacrolimus—Infection—Mycophenolate mofetil—systemic scleroderma	8.18e-05	0.000193	CcSEcCtD
Tacrolimus—Decreased appetite—Lisinopril—systemic scleroderma	8.17e-05	0.000193	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Lisinopril—systemic scleroderma	8.12e-05	0.000192	CcSEcCtD
Tacrolimus—Fatigue—Lisinopril—systemic scleroderma	8.11e-05	0.000192	CcSEcCtD
Tacrolimus—MTOR—Immune System—CSK—systemic scleroderma	8.11e-05	0.000881	CbGpPWpGaD
Tacrolimus—Shock—Mycophenolate mofetil—systemic scleroderma	8.1e-05	0.000192	CcSEcCtD
Tacrolimus—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.08e-05	0.000191	CcSEcCtD
Tacrolimus—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.07e-05	0.000191	CcSEcCtD
Tacrolimus—Hypersensitivity—Leflunomide—systemic scleroderma	8.06e-05	0.000191	CcSEcCtD
Tacrolimus—Pancreatitis—Methotrexate—systemic scleroderma	8.05e-05	0.00019	CcSEcCtD
Tacrolimus—Constipation—Lisinopril—systemic scleroderma	8.04e-05	0.00019	CcSEcCtD
Tacrolimus—Pain—Lisinopril—systemic scleroderma	8.04e-05	0.00019	CcSEcCtD
Tacrolimus—Tachycardia—Mycophenolate mofetil—systemic scleroderma	8.04e-05	0.00019	CcSEcCtD
Tacrolimus—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8e-05	0.000189	CcSEcCtD
Tacrolimus—Bradycardia—Prednisone—systemic scleroderma	8e-05	0.000189	CcSEcCtD
Tacrolimus—MTOR—Immune System—IRF5—systemic scleroderma	7.97e-05	0.000866	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	7.96e-05	0.000188	CcSEcCtD
Tacrolimus—Diarrhoea—Azathioprine—systemic scleroderma	7.93e-05	0.000187	CcSEcCtD
Tacrolimus—Haemoglobin—Prednisone—systemic scleroderma	7.9e-05	0.000187	CcSEcCtD
Tacrolimus—Nausea—Captopril—systemic scleroderma	7.89e-05	0.000186	CcSEcCtD
Tacrolimus—Haemorrhage—Prednisone—systemic scleroderma	7.86e-05	0.000186	CcSEcCtD
Tacrolimus—Anorexia—Mycophenolate mofetil—systemic scleroderma	7.85e-05	0.000186	CcSEcCtD
Tacrolimus—Asthenia—Leflunomide—systemic scleroderma	7.85e-05	0.000186	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	7.84e-05	0.000852	CbGpPWpGaD
Tacrolimus—Hallucination—Prednisone—systemic scleroderma	7.82e-05	0.000185	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—CCL2—systemic scleroderma	7.8e-05	0.000847	CbGpPWpGaD
Tacrolimus—Pancytopenia—Methotrexate—systemic scleroderma	7.79e-05	0.000184	CcSEcCtD
Tacrolimus—MTOR—Disease—HSPG2—systemic scleroderma	7.75e-05	0.000842	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Lisinopril—systemic scleroderma	7.75e-05	0.000183	CcSEcCtD
Tacrolimus—Pruritus—Leflunomide—systemic scleroderma	7.74e-05	0.000183	CcSEcCtD
Tacrolimus—Connective tissue disorder—Prednisone—systemic scleroderma	7.72e-05	0.000183	CcSEcCtD
Tacrolimus—Hypotension—Mycophenolate mofetil—systemic scleroderma	7.7e-05	0.000182	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Lisinopril—systemic scleroderma	7.69e-05	0.000182	CcSEcCtD
Tacrolimus—Neutropenia—Methotrexate—systemic scleroderma	7.67e-05	0.000181	CcSEcCtD
Tacrolimus—Dysuria—Methotrexate—systemic scleroderma	7.67e-05	0.000181	CcSEcCtD
Tacrolimus—Dizziness—Azathioprine—systemic scleroderma	7.66e-05	0.000181	CcSEcCtD
Tacrolimus—MTOR—Immune System—ITGAM—systemic scleroderma	7.62e-05	0.000828	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IRF8—systemic scleroderma	7.62e-05	0.000828	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD247—systemic scleroderma	7.62e-05	0.000828	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—CSK—systemic scleroderma	7.6e-05	0.000825	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	7.51e-05	0.000177	CcSEcCtD
Tacrolimus—ALB—Platelet degranulation—TGFB1—systemic scleroderma	7.5e-05	0.000815	CbGpPWpGaD
Tacrolimus—Photosensitivity reaction—Methotrexate—systemic scleroderma	7.49e-05	0.000177	CcSEcCtD
Tacrolimus—Asthenia—Mycophenolic acid—systemic scleroderma	7.49e-05	0.000177	CcSEcCtD
Tacrolimus—Diarrhoea—Leflunomide—systemic scleroderma	7.49e-05	0.000177	CcSEcCtD
Tacrolimus—MTOR—Disease—CSK—systemic scleroderma	7.48e-05	0.000813	CbGpPWpGaD
Tacrolimus—Urticaria—Lisinopril—systemic scleroderma	7.47e-05	0.000177	CcSEcCtD
Tacrolimus—Insomnia—Mycophenolate mofetil—systemic scleroderma	7.45e-05	0.000176	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—SMAD7—systemic scleroderma	7.44e-05	0.000808	CbGpPWpGaD
Tacrolimus—Body temperature increased—Lisinopril—systemic scleroderma	7.43e-05	0.000176	CcSEcCtD
Tacrolimus—Abdominal pain—Lisinopril—systemic scleroderma	7.43e-05	0.000176	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—CD40LG—systemic scleroderma	7.41e-05	0.000805	CbGpPWpGaD
Tacrolimus—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	7.4e-05	0.000175	CcSEcCtD
Tacrolimus—Pruritus—Mycophenolic acid—systemic scleroderma	7.39e-05	0.000175	CcSEcCtD
Tacrolimus—Vomiting—Azathioprine—systemic scleroderma	7.37e-05	0.000174	CcSEcCtD
Tacrolimus—Pneumonia—Methotrexate—systemic scleroderma	7.36e-05	0.000174	CcSEcCtD
Tacrolimus—Eye disorder—Prednisone—systemic scleroderma	7.35e-05	0.000174	CcSEcCtD
Tacrolimus—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	7.34e-05	0.000174	CcSEcCtD
Tacrolimus—Somnolence—Mycophenolate mofetil—systemic scleroderma	7.32e-05	0.000173	CcSEcCtD
Tacrolimus—Infestation—Methotrexate—systemic scleroderma	7.32e-05	0.000173	CcSEcCtD
Tacrolimus—Infestation NOS—Methotrexate—systemic scleroderma	7.32e-05	0.000173	CcSEcCtD
Tacrolimus—Rash—Azathioprine—systemic scleroderma	7.31e-05	0.000173	CcSEcCtD
Tacrolimus—Dermatitis—Azathioprine—systemic scleroderma	7.3e-05	0.000173	CcSEcCtD
Tacrolimus—Depression—Methotrexate—systemic scleroderma	7.3e-05	0.000172	CcSEcCtD
Tacrolimus—Flushing—Prednisone—systemic scleroderma	7.29e-05	0.000172	CcSEcCtD
Tacrolimus—Headache—Azathioprine—systemic scleroderma	7.26e-05	0.000172	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	7.25e-05	0.000171	CcSEcCtD
Tacrolimus—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	7.25e-05	0.000171	CcSEcCtD
Tacrolimus—Dizziness—Leflunomide—systemic scleroderma	7.24e-05	0.000171	CcSEcCtD
Tacrolimus—Renal failure—Methotrexate—systemic scleroderma	7.19e-05	0.00017	CcSEcCtD
Tacrolimus—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.16e-05	0.000169	CcSEcCtD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.16e-05	0.000778	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	7.15e-05	0.000777	CbGpPWpGaD
Tacrolimus—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.14e-05	0.000169	CcSEcCtD
Tacrolimus—ALB—Hemostasis—ITGAM—systemic scleroderma	7.14e-05	0.000776	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TNFAIP3—systemic scleroderma	7.14e-05	0.000775	CbGpPWpGaD
Tacrolimus—Stomatitis—Methotrexate—systemic scleroderma	7.13e-05	0.000169	CcSEcCtD
Tacrolimus—Angiopathy—Prednisone—systemic scleroderma	7.13e-05	0.000169	CcSEcCtD
Tacrolimus—Conjunctivitis—Methotrexate—systemic scleroderma	7.11e-05	0.000168	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.11e-05	0.000168	CcSEcCtD
Tacrolimus—Immune system disorder—Prednisone—systemic scleroderma	7.1e-05	0.000168	CcSEcCtD
Tacrolimus—MTOR—Immune System—BLK—systemic scleroderma	7.05e-05	0.000766	CbGpPWpGaD
Tacrolimus—Pain—Mycophenolate mofetil—systemic scleroderma	7.04e-05	0.000167	CcSEcCtD
Tacrolimus—Constipation—Mycophenolate mofetil—systemic scleroderma	7.04e-05	0.000167	CcSEcCtD
Tacrolimus—MTOR—Disease—CD247—systemic scleroderma	7.04e-05	0.000764	CbGpPWpGaD
Tacrolimus—Arrhythmia—Prednisone—systemic scleroderma	7.02e-05	0.000166	CcSEcCtD
Tacrolimus—Sweating—Methotrexate—systemic scleroderma	7.01e-05	0.000166	CcSEcCtD
Tacrolimus—Haematuria—Methotrexate—systemic scleroderma	6.98e-05	0.000165	CcSEcCtD
Tacrolimus—Vomiting—Leflunomide—systemic scleroderma	6.96e-05	0.000164	CcSEcCtD
Tacrolimus—Alopecia—Prednisone—systemic scleroderma	6.95e-05	0.000164	CcSEcCtD
Tacrolimus—Hypersensitivity—Lisinopril—systemic scleroderma	6.93e-05	0.000164	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Methotrexate—systemic scleroderma	6.92e-05	0.000164	CcSEcCtD
Tacrolimus—Dizziness—Mycophenolic acid—systemic scleroderma	6.9e-05	0.000163	CcSEcCtD
Tacrolimus—Epistaxis—Methotrexate—systemic scleroderma	6.9e-05	0.000163	CcSEcCtD
Tacrolimus—Rash—Leflunomide—systemic scleroderma	6.9e-05	0.000163	CcSEcCtD
Tacrolimus—Dermatitis—Leflunomide—systemic scleroderma	6.89e-05	0.000163	CcSEcCtD
Tacrolimus—Mental disorder—Prednisone—systemic scleroderma	6.89e-05	0.000163	CcSEcCtD
Tacrolimus—Nausea—Azathioprine—systemic scleroderma	6.88e-05	0.000163	CcSEcCtD
Tacrolimus—Headache—Leflunomide—systemic scleroderma	6.85e-05	0.000162	CcSEcCtD
Tacrolimus—Erythema—Prednisone—systemic scleroderma	6.84e-05	0.000162	CcSEcCtD
Tacrolimus—Malnutrition—Prednisone—systemic scleroderma	6.84e-05	0.000162	CcSEcCtD
Tacrolimus—Agranulocytosis—Methotrexate—systemic scleroderma	6.83e-05	0.000161	CcSEcCtD
Tacrolimus—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	6.79e-05	0.00016	CcSEcCtD
Tacrolimus—Asthenia—Lisinopril—systemic scleroderma	6.75e-05	0.000159	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—EDN1—systemic scleroderma	6.74e-05	0.000732	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	6.74e-05	0.000159	CcSEcCtD
Tacrolimus—Pruritus—Lisinopril—systemic scleroderma	6.65e-05	0.000157	CcSEcCtD
Tacrolimus—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	6.64e-05	0.000721	CbGpPWpGaD
Tacrolimus—Vomiting—Mycophenolic acid—systemic scleroderma	6.64e-05	0.000157	CcSEcCtD
Tacrolimus—Haemoglobin—Methotrexate—systemic scleroderma	6.6e-05	0.000156	CcSEcCtD
Tacrolimus—Rash—Mycophenolic acid—systemic scleroderma	6.58e-05	0.000156	CcSEcCtD
Tacrolimus—Dermatitis—Mycophenolic acid—systemic scleroderma	6.58e-05	0.000155	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—systemic scleroderma	6.57e-05	0.000155	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—systemic scleroderma	6.57e-05	0.000155	CcSEcCtD
Tacrolimus—Urticaria—Mycophenolate mofetil—systemic scleroderma	6.54e-05	0.000155	CcSEcCtD
Tacrolimus—Headache—Mycophenolic acid—systemic scleroderma	6.54e-05	0.000155	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—systemic scleroderma	6.52e-05	0.000154	CcSEcCtD
Tacrolimus—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	6.51e-05	0.000154	CcSEcCtD
Tacrolimus—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	6.51e-05	0.000154	CcSEcCtD
Tacrolimus—Nausea—Leflunomide—systemic scleroderma	6.5e-05	0.000154	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—systemic scleroderma	6.49e-05	0.000153	CcSEcCtD
Tacrolimus—Vision blurred—Prednisone—systemic scleroderma	6.45e-05	0.000152	CcSEcCtD
Tacrolimus—Urethral disorder—Methotrexate—systemic scleroderma	6.44e-05	0.000152	CcSEcCtD
Tacrolimus—Diarrhoea—Lisinopril—systemic scleroderma	6.43e-05	0.000152	CcSEcCtD
Tacrolimus—Ill-defined disorder—Prednisone—systemic scleroderma	6.35e-05	0.00015	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—systemic scleroderma	6.33e-05	0.00015	CcSEcCtD
Tacrolimus—Anaemia—Prednisone—systemic scleroderma	6.32e-05	0.000149	CcSEcCtD
Tacrolimus—Agitation—Prednisone—systemic scleroderma	6.29e-05	0.000149	CcSEcCtD
Tacrolimus—Dizziness—Lisinopril—systemic scleroderma	6.22e-05	0.000147	CcSEcCtD
Tacrolimus—Erythema multiforme—Methotrexate—systemic scleroderma	6.21e-05	0.000147	CcSEcCtD
Tacrolimus—Nausea—Mycophenolic acid—systemic scleroderma	6.2e-05	0.000147	CcSEcCtD
Tacrolimus—Malaise—Prednisone—systemic scleroderma	6.17e-05	0.000146	CcSEcCtD
Tacrolimus—Vertigo—Prednisone—systemic scleroderma	6.15e-05	0.000145	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—systemic scleroderma	6.14e-05	0.000145	CcSEcCtD
Tacrolimus—Syncope—Prednisone—systemic scleroderma	6.14e-05	0.000145	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—systemic scleroderma	6.12e-05	0.000145	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—systemic scleroderma	6.1e-05	0.000144	CcSEcCtD
Tacrolimus—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	6.07e-05	0.000143	CcSEcCtD
Tacrolimus—Loss of consciousness—Prednisone—systemic scleroderma	6.01e-05	0.000142	CcSEcCtD
Tacrolimus—Vomiting—Lisinopril—systemic scleroderma	5.98e-05	0.000141	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—systemic scleroderma	5.96e-05	0.000141	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—systemic scleroderma	5.93e-05	0.00014	CcSEcCtD
Tacrolimus—Rash—Lisinopril—systemic scleroderma	5.93e-05	0.00014	CcSEcCtD
Tacrolimus—Convulsion—Prednisone—systemic scleroderma	5.93e-05	0.00014	CcSEcCtD
Tacrolimus—Dermatitis—Lisinopril—systemic scleroderma	5.92e-05	0.00014	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—systemic scleroderma	5.92e-05	0.00014	CcSEcCtD
Tacrolimus—Asthenia—Mycophenolate mofetil—systemic scleroderma	5.91e-05	0.00014	CcSEcCtD
Tacrolimus—Hypertension—Prednisone—systemic scleroderma	5.91e-05	0.00014	CcSEcCtD
Tacrolimus—Chills—Methotrexate—systemic scleroderma	5.89e-05	0.000139	CcSEcCtD
Tacrolimus—Headache—Lisinopril—systemic scleroderma	5.89e-05	0.000139	CcSEcCtD
Tacrolimus—PPP3CA—Disease—NOS3—systemic scleroderma	5.86e-05	0.000637	CbGpPWpGaD
Tacrolimus—Pruritus—Mycophenolate mofetil—systemic scleroderma	5.83e-05	0.000138	CcSEcCtD
Tacrolimus—Arthralgia—Prednisone—systemic scleroderma	5.83e-05	0.000138	CcSEcCtD
Tacrolimus—Myalgia—Prednisone—systemic scleroderma	5.83e-05	0.000138	CcSEcCtD
Tacrolimus—Anxiety—Prednisone—systemic scleroderma	5.8e-05	0.000137	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—systemic scleroderma	5.8e-05	0.000137	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	5.78e-05	0.000137	CcSEcCtD
Tacrolimus—MTOR—Immune System—CTLA4—systemic scleroderma	5.78e-05	0.000627	CbGpPWpGaD
Tacrolimus—Discomfort—Prednisone—systemic scleroderma	5.76e-05	0.000136	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—systemic scleroderma	5.75e-05	0.000136	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—RHOB—systemic scleroderma	5.75e-05	0.000625	CbGpPWpGaD
Tacrolimus—Erythema—Methotrexate—systemic scleroderma	5.72e-05	0.000135	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—systemic scleroderma	5.72e-05	0.000135	CcSEcCtD
Tacrolimus—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	5.64e-05	0.000133	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—systemic scleroderma	5.6e-05	0.000132	CcSEcCtD
Tacrolimus—Nausea—Lisinopril—systemic scleroderma	5.58e-05	0.000132	CcSEcCtD
Tacrolimus—Anaphylactic shock—Prednisone—systemic scleroderma	5.58e-05	0.000132	CcSEcCtD
Tacrolimus—Oedema—Prednisone—systemic scleroderma	5.58e-05	0.000132	CcSEcCtD
Tacrolimus—Infection—Prednisone—systemic scleroderma	5.55e-05	0.000131	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—systemic scleroderma	5.53e-05	0.000131	CcSEcCtD
Tacrolimus—Shock—Prednisone—systemic scleroderma	5.49e-05	0.00013	CcSEcCtD
Tacrolimus—Nervous system disorder—Prednisone—systemic scleroderma	5.48e-05	0.000129	CcSEcCtD
Tacrolimus—Tachycardia—Prednisone—systemic scleroderma	5.45e-05	0.000129	CcSEcCtD
Tacrolimus—Dizziness—Mycophenolate mofetil—systemic scleroderma	5.45e-05	0.000129	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—HSPG2—systemic scleroderma	5.43e-05	0.00059	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.43e-05	0.000589	CbGpPWpGaD
Tacrolimus—Skin disorder—Prednisone—systemic scleroderma	5.42e-05	0.000128	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—IL1B—systemic scleroderma	5.4e-05	0.000587	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Prednisone—systemic scleroderma	5.4e-05	0.000128	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—systemic scleroderma	5.39e-05	0.000127	CcSEcCtD
Tacrolimus—Anorexia—Prednisone—systemic scleroderma	5.32e-05	0.000126	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—systemic scleroderma	5.31e-05	0.000125	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—systemic scleroderma	5.29e-05	0.000125	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—CSK—systemic scleroderma	5.24e-05	0.000569	CbGpPWpGaD
Tacrolimus—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.24e-05	0.000124	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—EDN1—systemic scleroderma	5.22e-05	0.000568	CbGpPWpGaD
Tacrolimus—Rash—Mycophenolate mofetil—systemic scleroderma	5.19e-05	0.000123	CcSEcCtD
Tacrolimus—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.19e-05	0.000123	CcSEcCtD
Tacrolimus—Headache—Mycophenolate mofetil—systemic scleroderma	5.16e-05	0.000122	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—systemic scleroderma	5.16e-05	0.000122	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—systemic scleroderma	5.14e-05	0.000121	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—HSPG2—systemic scleroderma	5.12e-05	0.000556	CbGpPWpGaD
Tacrolimus—Leukopenia—Methotrexate—systemic scleroderma	5.12e-05	0.000121	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.09e-05	0.00012	CcSEcCtD
Tacrolimus—Insomnia—Prednisone—systemic scleroderma	5.05e-05	0.000119	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisone—systemic scleroderma	5.01e-05	0.000119	CcSEcCtD
Tacrolimus—Cough—Methotrexate—systemic scleroderma	4.99e-05	0.000118	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—systemic scleroderma	4.95e-05	0.000117	CcSEcCtD
Tacrolimus—Dyspepsia—Prednisone—systemic scleroderma	4.92e-05	0.000116	CcSEcCtD
Tacrolimus—Nausea—Mycophenolate mofetil—systemic scleroderma	4.89e-05	0.000116	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—systemic scleroderma	4.87e-05	0.000115	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—systemic scleroderma	4.87e-05	0.000115	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—systemic scleroderma	4.87e-05	0.000115	CcSEcCtD
Tacrolimus—Decreased appetite—Prednisone—systemic scleroderma	4.85e-05	0.000115	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	4.83e-05	0.000114	CcSEcCtD
Tacrolimus—Fatigue—Prednisone—systemic scleroderma	4.81e-05	0.000114	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—systemic scleroderma	4.81e-05	0.000114	CcSEcCtD
Tacrolimus—Constipation—Prednisone—systemic scleroderma	4.78e-05	0.000113	CcSEcCtD
Tacrolimus—MTOR—Immune System—HLA-DQB1—systemic scleroderma	4.76e-05	0.000517	CbGpPWpGaD
Tacrolimus—Confusional state—Methotrexate—systemic scleroderma	4.71e-05	0.000111	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—systemic scleroderma	4.67e-05	0.00011	CcSEcCtD
Tacrolimus—Infection—Methotrexate—systemic scleroderma	4.64e-05	0.00011	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CCL2—systemic scleroderma	4.61e-05	0.0005	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Prednisone—systemic scleroderma	4.6e-05	0.000109	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—systemic scleroderma	4.58e-05	0.000108	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—systemic scleroderma	4.57e-05	0.000108	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Prednisone—systemic scleroderma	4.57e-05	0.000108	CcSEcCtD
Tacrolimus—FKBP1A—Disease—NOS3—systemic scleroderma	4.55e-05	0.000494	CbGpPWpGaD
Tacrolimus—Skin disorder—Methotrexate—systemic scleroderma	4.53e-05	0.000107	CcSEcCtD
Tacrolimus—MTOR—Immune System—IL1A—systemic scleroderma	4.52e-05	0.000491	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Methotrexate—systemic scleroderma	4.51e-05	0.000107	CcSEcCtD
Tacrolimus—MTOR—Immune System—CD40LG—systemic scleroderma	4.49e-05	0.000488	CbGpPWpGaD
Tacrolimus—Anorexia—Methotrexate—systemic scleroderma	4.45e-05	0.000105	CcSEcCtD
Tacrolimus—Urticaria—Prednisone—systemic scleroderma	4.44e-05	0.000105	CcSEcCtD
Tacrolimus—Abdominal pain—Prednisone—systemic scleroderma	4.41e-05	0.000104	CcSEcCtD
Tacrolimus—Body temperature increased—Prednisone—systemic scleroderma	4.41e-05	0.000104	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—systemic scleroderma	4.36e-05	0.000103	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.25e-05	0.000101	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—systemic scleroderma	4.22e-05	9.98e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—systemic scleroderma	4.19e-05	9.91e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—systemic scleroderma	4.16e-05	9.83e-05	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—systemic scleroderma	4.15e-05	9.81e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisone—systemic scleroderma	4.11e-05	9.73e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—systemic scleroderma	4.11e-05	9.71e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—NOS3—systemic scleroderma	4.1e-05	0.000446	CbGpPWpGaD
Tacrolimus—Decreased appetite—Methotrexate—systemic scleroderma	4.06e-05	9.59e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.03e-05	9.52e-05	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—systemic scleroderma	4.02e-05	9.51e-05	CcSEcCtD
Tacrolimus—Asthenia—Prednisone—systemic scleroderma	4.01e-05	9.47e-05	CcSEcCtD
Tacrolimus—Pain—Methotrexate—systemic scleroderma	3.99e-05	9.43e-05	CcSEcCtD
Tacrolimus—Pruritus—Prednisone—systemic scleroderma	3.95e-05	9.34e-05	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—CTGF—systemic scleroderma	3.88e-05	0.000422	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—TGFB1—systemic scleroderma	3.88e-05	0.000421	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Methotrexate—systemic scleroderma	3.85e-05	9.09e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Prednisone—systemic scleroderma	3.82e-05	9.03e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.82e-05	9.02e-05	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—systemic scleroderma	3.71e-05	8.76e-05	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—HSPG2—systemic scleroderma	3.7e-05	0.000402	CbGpPWpGaD
Tacrolimus—Dizziness—Prednisone—systemic scleroderma	3.69e-05	8.73e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—systemic scleroderma	3.69e-05	8.72e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—systemic scleroderma	3.69e-05	8.72e-05	CcSEcCtD
Tacrolimus—ALB—Hemostasis—MMP1—systemic scleroderma	3.58e-05	0.000389	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCL2—systemic scleroderma	3.57e-05	0.000388	CbGpPWpGaD
Tacrolimus—Vomiting—Prednisone—systemic scleroderma	3.55e-05	8.39e-05	CcSEcCtD
Tacrolimus—Rash—Prednisone—systemic scleroderma	3.52e-05	8.32e-05	CcSEcCtD
Tacrolimus—Dermatitis—Prednisone—systemic scleroderma	3.52e-05	8.31e-05	CcSEcCtD
Tacrolimus—Headache—Prednisone—systemic scleroderma	3.5e-05	8.27e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—systemic scleroderma	3.44e-05	8.13e-05	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—systemic scleroderma	3.35e-05	7.91e-05	CcSEcCtD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.33e-05	0.000362	CbGpPWpGaD
Tacrolimus—Nausea—Prednisone—systemic scleroderma	3.32e-05	7.84e-05	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—systemic scleroderma	3.3e-05	7.8e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—systemic scleroderma	3.29e-05	0.000358	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.28e-05	0.000356	CbGpPWpGaD
Tacrolimus—Diarrhoea—Methotrexate—systemic scleroderma	3.19e-05	7.55e-05	CcSEcCtD
Tacrolimus—ALB—Metabolism—HSPG2—systemic scleroderma	3.19e-05	0.000346	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NOS3—systemic scleroderma	3.18e-05	0.000346	CbGpPWpGaD
Tacrolimus—Dizziness—Methotrexate—systemic scleroderma	3.09e-05	7.29e-05	CcSEcCtD
Tacrolimus—FKBP1A—Disease—TGFB1—systemic scleroderma	3.01e-05	0.000327	CbGpPWpGaD
Tacrolimus—Vomiting—Methotrexate—systemic scleroderma	2.97e-05	7.01e-05	CcSEcCtD
Tacrolimus—Rash—Methotrexate—systemic scleroderma	2.94e-05	6.96e-05	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—systemic scleroderma	2.94e-05	6.95e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—EDN1—systemic scleroderma	2.94e-05	0.000319	CbGpPWpGaD
Tacrolimus—Headache—Methotrexate—systemic scleroderma	2.92e-05	6.91e-05	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—CTGF—systemic scleroderma	2.81e-05	0.000305	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.79e-05	0.000304	CbGpPWpGaD
Tacrolimus—Nausea—Methotrexate—systemic scleroderma	2.77e-05	6.55e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—TGFB1—systemic scleroderma	2.71e-05	0.000295	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NOS3—systemic scleroderma	2.59e-05	0.000282	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOS3—systemic scleroderma	2.56e-05	0.000278	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—systemic scleroderma	2.55e-05	0.000277	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CTGF—systemic scleroderma	2.42e-05	0.000263	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1B—systemic scleroderma	2.36e-05	0.000256	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CTGF—systemic scleroderma	2.12e-05	0.00023	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—systemic scleroderma	2.1e-05	0.000229	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL2—systemic scleroderma	2.01e-05	0.000218	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOS3—systemic scleroderma	1.79e-05	0.000194	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.72e-05	0.000187	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—systemic scleroderma	1.72e-05	0.000186	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—systemic scleroderma	1.69e-05	0.000184	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NOS3—systemic scleroderma	1.69e-05	0.000184	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—systemic scleroderma	1.44e-05	0.000156	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.3e-05	0.000142	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.22e-05	0.000133	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—systemic scleroderma	1.18e-05	0.000129	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NOS3—systemic scleroderma	1.05e-05	0.000114	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NOS3—systemic scleroderma	9.22e-06	0.0001	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NOS3—systemic scleroderma	5.68e-06	6.17e-05	CbGpPWpGaD
